AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in ...

Presented updated clinical and biomarker activity data at the IOVC in October 2024. Investigators reported ongoing improved ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...

Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

These updates will benefit about 66,000 people annually. The National Health Insurance Administration (NHIA) has added 30 ...

Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging, prostate ...

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from ...

CVGBM, an investigational cancer vaccine, induced T-cell responses in patients with MGMT-unmethylated glioblastoma.

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and destroy cancer cells.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...